Urso Related Published Studies
Well-designed clinical trials related to Urso (Ursodiol)
Efficacy and safety of ursodeoxycholic acid in primary, type IIa or IIb hypercholesterolemia: A multicenter, randomized, double-blind clinical trial. [2008.08.12]
Clinical Trial: Randomized controlled trial of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. [2008.07.09]
Ursodeoxycholic acid treatment in preterm infants: a pilot study for the prevention of cholestasis associated with total parenteral nutrition. [2008.02]
Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid. [2007.06.27]
Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones. [2007.06]
Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. [2006.12]
Ursodeoxycholic acid exerts no beneficial effect in patients with symptomatic gallstones awaiting cholecystectomy. [2006.06]
[Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)] [2006.03]
Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. [2006]
Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. [2005.12]
High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. [2005.11]
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. [2005.11]
Short-term ursodeoxycholic acid treatment improves gallbladder bile turnover in gallstone patients: a randomized trial. [2005.10]
Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. [2005.09]
Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. [2005.08]
Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. [2005.06.01]
Bioequivalence of a new liquid formulation of ursodeoxycholic acid (Ursofalk suspension) and Ursofalk capsules measured by plasma pharmacokinetics and biliary enrichment. [2005.03.15]
Well-designed clinical trials possibly related to Urso (Ursodiol)
The effect of a quality improvement collaborative to improve antimicrobial prophylaxis in surgical patients: a randomized trial. [2008.10.07]
Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. [2008.07]
Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. [2008.05.07]
Effectiveness of Danning Tablet in patients with non-alcoholic fatty liver of damp-heat syndrome type: A multicenter randomized controlled trial. [2008.03]
Intrahepatic cholestasis of pregnancy: Amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. [2008.02]
Effectiveness of Danning Tablet in patients with non-alcoholic fatty liver of damp-heat syndrome type: a multicenter randomized controlled trial. [2008.02]
Skeletonization of the internal thoracic artery: a randomized comparison of harvesting methods. [2008.02]
Effects of long term hydrophilic bile acid therapy on in vitro contraction of gallbladder muscle strips in patients with cholesterol gallstones. [2007.08.28]
Kasai portoenterostomy: 12-year experience with a novel adjuvant therapy regimen. [2007.08]
Folate fortification, plasma folate, homocysteine and colorectal adenoma recurrence. [2006.09.15]
Effects of choleretics on bile compositions drained from patients with pigment gallstone. [2006.06]
Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy. [2005.08]
Karyometry in rectal mucosa of patients with previous colorectal adenomas. [2005.06]
Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. [2005.04]
Failure of cholecystokinin-octapeptide to prevent TPN-associated gallstone disease. [2005.01]
Other research related to Urso (Ursodiol)
[A case of probable autoimmune hepatitis from which the persistence of hepatitis A IgM antibody, and the improvement was pathologically obtained by ursodeoxycholic acid medication] [2008.09]
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. [2008.09]
Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin. [2008.08]
Ursodeoxycholic acid for primary biliary cirrhosis. [2008.07.16]
Ursodeoxycholic acid treatment for patients with postcholecystectomy pain and bile microlithiasis. [2008.07]
Review of historical cohort: ursodeoxycholic acid in extrahepatic biliary atresia. [2008.07]
Ursodeoxycholic Acid in the Prevention of Gallstone Formation after Bariatric Surgery: A Meta-analysis. [2008.06.24]
The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study. [2008.06]
Combination of endoprostheses and oral ursodeoxycholic acid or placebo in the treatment of difficult to extract common bile duct stones. [2008.06]
Effects of ursodeoxycholic acid on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam in healthy volunteers. [2008.06]
High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. [2008.05]
HNF1{alpha} INHIBITOR URSODEOXYCHOLIC ACID (UDCA) INFLUENCES PHARMACOKINETICS OF the OATP1B1 SUBSTRATE ROSUVASTATIN AND BILIRUBIN. [2008.04.28]
Role of ursodeoxycholic acid in prevention of methotrexate-induced liver toxicity. [2008.04]
Tauroursodeoxycholic acid reduces bile acid-induced apoptosis by modulation of AP-1. [2008.02.29]
High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. [2008.02.14]
Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. [2008.02]
Combination of endoprostheses and oral ursodeoxycholic acid or placebo in the treatment of difficult to extract common bile duct stones. [2008.01.08]
Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-alpha and macrophage inflammatory protein-2 production. [2008.01.06]
Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis. [2008.01]
Process optimization, characterization and pharmacokinetic evaluation in rats of ursodeoxycholic acid-phospholipid complex. [2008]
The effect of oral administration of ursodeoxycholic acid and high-dose proton pump inhibitors on the histology of Barrett's esophagus. [2008]
Effects of ursodeoxycholic acid on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam in healthy volunteers. [2007.12.19]
A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. [2007.12]
The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid. [2007.12]
Ursodiol in patients with parenteral nutrition-associated cholestasis. [2007.11]
Gradual improvement of liver function after administration of ursodeoxycholic acid in an infant with a novel ABCB11 gene mutation with phenotypic continuum between BRIC2 and PFIC2. [2007.11]
Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid. [2007.10.15]
Ursodiol in Patients with Parenteral Nutrition-Associated Cholestasis (November). [2007.10.02]
Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. [2007.10]
Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. [2007.09]
Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. [2007.09]
[Effect of ursodeoxycholic acid in an experimental colon cancer model] [2007.09]
A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. [2007.08.30]
Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. [2007.08]
Psoriasis treated with ursodeoxycholic acid: three case reports. [2007.07]
A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. [2007.06.25]
Protective effect of ursodeoxycholic acid on liver mitochondrial function in rats with alloxan-induced diabetes: link with oxidative stress. [2007.06.06]
The importance of serum bile acid level analysis and treatment with ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a case series from central Europe. [2007.06]
The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. [2007.06]
Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases. [2007.05]
Ursodeoxycholic Acid for Patients With Primary Biliary Cirrhosis: An Updated Systematic Review and Meta-Analysis of Randomized Clinical Trials Using Bayesian Approach as Sensitivity Analyses. [2007.04.24]
Ursodeoxycholic acid versus sulfasalazine in colitis-related colon carcinogenesis in mice. [2007.04.15]
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. [2007.03]
Systematic Review of Controlled Clinical Trials on the Use of Ursodeoxycholic Acid for the Prevention of Hepatic Veno-occlusive Disease in Hematopoietic Stem Cell Transplantation. [2007.02]
The effects of somatostatin and ursodeoxycholic acid in preventing the ischemic injury of the liver following Pringle maneuver in obstructive jaundice-rat model. [2007.01]
Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones. [2006.12.21]
Identification of a novel 974C-->G nonsense mutation of the MRP2/ABCC2 gene in a patient with Dubin-Johnson syndrome and analysis of the effects of rifampicin and ursodeoxycholic acid on serum bilirubin and bile acids. [2006.10]
Ursodeoxycholic acid improves gastrointestinal motility defects in gallstone patients. [2006.09.07]
Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy. [2006.09.01]
Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. [2006.09]
[Granulomatous hepatitis successfully treated with ursodeoxycholic acid] [2006.08.06]
Early treatment with ursodeoxycholic acid for cholestasis in children on parenteral nutrition because of primary intestinal failure. [2006.07.15]
Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. [2006.07]
Ursodeoxycholic acid treatment of vanishing bile duct syndromes. [2006.06.14]
Prevention of colitis-associated carcinogenesis in a mouse model by diet supplementation with ursodeoxycholic acid. [2006.06.01]
Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. [2006.06]
Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans. [2006.05]
Role of ursodeoxycholic acid in lowering ALT in chronic liver disease. [2006.03]
Effect of colitis and ileoanal pouch on biliary enrichment of ursodeoxycholic acid in primary sclerosing cholangitis. [2006.03]
Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. [2006.03]
Rat liver fibrosis regresses better with pegylated interferon alpha2b and ursodeoxycholic acid treatments than spontaneous recovery. [2006.03]
[Predisposing factors and results of pharmalogical treatment using ursodeoxycholic acid of gallbladder stones in children] [2006.02]
24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. [2006.02]
Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts. [2006.02]
Ursodeoxycholic acid therapy for intractable total parenteral nutrition-associated cholestasis in surgical very low birth weight infants. [2006.02]
Maternal cholestasis induces placental oxidative stress and apoptosis. Protective effect of ursodeoxycholic acid. [2006.01]
Ursodeoxycholic acid in the treatment of intraheptic cholestasis of pregnancy. [2006]
Antioxidant mechanism of hepatoprotection by ursodeoxycholic acid in experimental alcoholic steatohepatitis. [2006]
Ursodesoxycholic acid and heme-arginate are unable to improve hematopoiesis and liver injury in an erythropoietic protoporphyria mouse model. [2006]
|
